Characteristic patterns of microrna expression in human bladder cancer

Frontiers in Genetics

Volumn 3, Issue JAN, 2013, Pages

  Zabolotneva, Anastasia A ^a,b   Zhavoronkov, Alex ^a   Garazha, Andrew V ^a,b   Roumiantsev, Sergey A ^a   Buzdin, Anton A ^a,b  

^a Federal Research Center of Pediatric Hematology   (Russian Federation)

^b SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Biomarker; Bladder cancer; Microrna; Urothelial cancer

Indexed keywords

EID: 84876176695     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00310     Document Type: Short Survey

References (37)

1. Adam, L., Wszolek, M. F., Liu, C. G., Jing, W., Diao, L., Zien, A., et al. (2012). Plasma microRNA profiles for bladder cancer detection. Urol. Oncol. doi: 10.1016/j.urolonc.2012.06.010 [Epub ahead of print].
2. Allegra, A., Alonci, A., Campo, S., Penna, G., Petrungaro, A., Gerace, D., et al. (2012). Circulating microR-NAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review). Int. J. Oncol. 41, 1897-1912.
3. Billerey, C., Chopin, D., Aubriot-Lorton, M. H., Ricol, D., Gil Diez De Medina, S., Van Rhijn, B., et al. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955-1959.
4. Brennan, P., Bogillot, O., Cordier, S., Greiser, E., Schill, W., Vineis, P., et al. (2000). Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int. J. Cancer 86,289-294.
5. Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. U.S.A. 101,2999-3004.
6. Cappellen, D., De Oliveira, C., Ricol, D., De Medina, S., Bourdin, J., Sastre-Garau, X., et al. (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20.
7. Catto, J. W., Miah, S., Owen, H. C., Bryant, H., Myers, K., Dudziec, E., et al. (2009). Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 69,8472-8481.
8. Corsini, L. R., Bronte, G., Terrasi, M., Amodeo, V., Fanale, D., Fiorentino, E., et al. (2012). The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin. Ther. Targets 16(Suppl. 2), S103-S109.
9. Cortez, M. A., Welsh, J. W., and Calin, G. A. (2012). Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 195, 151-161.
10. Dyrskjot, L., Ostenfeld, M. S., Bramsen, J. B., Silahtaroglu, A. N., Lamy, P., Ramanathan, R., et al. (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69, 4851-4860.
11. Fendler, A., Stephan, C., Yousef, G. M., and Jung, K. (2011). MicroRNAs as regulators of signal transduction in urological tumors. Clin. Chem. 57, 954-968.
12. Golijanin, D. J., Kakiashvili, D., Madeb, R. R., Messing, E. M., and Lerner, S. P. (2006). Chemoprevention of bladder cancer. World J. Urol. 24, 445-472.
13. Ichimi, T., Enokida, H., Okuno, Y., Kunimoto, R., Chiyomaru, T., Kawamoto, K., et al. (2009). Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer 125, 345-352.
14. Jacobs, B. L., Lee, C. T., and Montie, J. E. (2010). Bladder cancer in 2010: how far have we come? CA Cancer J. Clin. 60,244-272.
15. Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., and Knowles, M. A. (2005). FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24,5218-5225.
16. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
17. Kaikkonen, M. U., Lam, M. T., and Glass, C. K. (2011). Noncoding RNAs as regulators of gene expression and epigenetics. Cardiovasc. Res. 90, 430-440.
18. Kent, O. A., Chivukula, R. R., Mullendore, M., Wentzel, E. A., Feldmann, G., Lee, K. H., et al. (2010). Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 24, 2754-2759.
19. Knowles, M. A. (2008). Molecular pathogenesis of bladder cancer. Int. J. Clin. Oncol. 13,287-297.
20. Kusenda, B., Mraz, M., Mayer, J., and Pospisilova, S. (2006). MicroRNA biogenesis, functionality and cancer relevance. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 150,205-215.
21. Lin, T., Dong, W., Huang, J., Pan, Q., Fan, X., Zhang, C., et al. (2009). MicroRNA-143 as a tumor suppressor for bladder cancer. J. Urol. 181, 1372-1380.
22. Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zochbauer-Muller, S., et al. (2001). Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61, 8659- 8663.
23. Moriya, Y., Nohata, N., Kinoshita, T., Mutallip, M., Okamoto, T., Yoshida, S., et al. (2012). Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J. Hum. Genet. 57, 38-45.
24. Mostafa, M. H., Sheweita, S. A., and O'Connor, P. J. (1999). Relationship between schistosomiasis and bladder cancer. Clin. Microbiol. Rev. 12, 97-111.
25. Ploeg, M., Aben, K. K., and Kiemeney, L. A. (2009). The present and future burden of urinary bladder cancer in the world. World J. Urol. 27,289-293.
26. Pritchard, C. C., Cheng, H. H., and Tewari, M. (2012). MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13, 358-369.
27. Qi, J., and Mu, D. (2012). MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front. Med. 6:134-155. doi: 10.1007/s11684-012-0188-4
28. Sandhu, J. S., Vickers, A. J., Bochner, B., Donat, S. M., Herr, H. W., and Dalbagni, G. (2006). Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJUInt. 98, 59-62.
29. Shenouda, S. K., and Alahari, S. K. (2009). MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28, 369-378.
30. Shokeir, A. A. (2004). Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 93, 216-220.
31. Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., et al. (1991). Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706-709.
32. Song, J. H., and Meltzer, S. J. (2011). MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143, 35-47.e32.
33. Van Tilborg, A. A., Bangma, C. H., and Zwarthoff, E. C. (2009). Bladder cancer biomarkers and their role in surveillance and screening. Int. J. Urol. 16,23-30.
34. Veerla, S., Lindgren, D., Kvist, A., Frigyesi, A., Staaf, J., Persson, H., et al. (2009). MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 124, 2236-2242.
35. Vineis, P., and Pirastu, R. (1997). Aromatic amines and cancer. Cancer Causes Control 8, 346-355.
36. Wang, G., Chan, E. S., Kwan, B. C., Li, P. K., Yip, S. K., Szeto, C. C., et al. (2012). Expression of microRNAs in the urine of patients with bladder cancer. Clin. Genitourin. Cancer 10, 106-113.
37. Yamada, Y., Enokida, H., Kojima, S., Kawakami, K., Chiyomaru, T., Tatarano, S., et al. (2011). MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 102, 522-529.